Targeting BCL-2 overexpression in various human malignancies through NF-κB inhibition by the proteasome inhibitor bortezomib

Medicine & Life Sciences

• Bortezomib 73%
• Proteasome Inhibitors 71%
• Cell Line 23%
• Neoplasms 19%
• Transcriptional Activation 18%
• ATP dependent 26S protease 13%
• Genes 12%
• Mutation 11%
• Mitogen-Activated Protein Kinase Kinases 10%
• MCF-7 Cells 10%
• Proteasome Endopeptidase Complex 10%
• Phosphatidylinositol 3-Kinase 10%
• Prostate 8%
• Signal Transduction 7%
• Breast 7%
• Apoptosis 6%
• Gene Expression 5%
• Lung 5%

Chemical Compounds

• Bortezomib 100%
• Proteasome Inhibitor 89%
• Mutation 50%
• Apoptotic 34%
• Signal Transduction 32%
• Protein 12%